NLS Pharmaceutics (NLSP)
(Delayed Data from NSDQ)
$2.14 USD
+0.12 (5.94%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $2.13 -0.01 (-0.47%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
NLSP 2.14 +0.12(5.94%)
Will NLSP be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NLSP based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for NLSP
NLS Pharmaceutics (NLSP) Gains BIRD Foundation Support for Diabetes Therapy | NLSP Stock News
NLS Pharmaceutics Highlights Continued Progress in iTOL-102 Diabetes Program as BIRD Foundation ...
NLS Pharmaceutics merger partner Kadimastem wins milestone payment
Why Greenbrier Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket
NLS Pharmaceutics and Kadimastem Announce Pricing and Closing of $1 Million Equity Financing | ...